MÉTODO DE TRATAMENTO COM RAPAMICINA E COMPOSIÇÃO
A topical Rapamycin composition with Monolaurin and Monomyristin addresses Rapamycin's accumulation issue, effectively treating vascular skin abnormalities while preventing bloodstream accumulation and ensuring safety.
Patent Information
- Application Number
- BR112025024678
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-20
- Filing Date
- 2024-04-02
- Publication Date
- 2026-11-10
AI Technical Summary
Rapamycin accumulates in the bloodstream over time, leading to adverse side effects and poses risks during pregnancy due to its classification as a Category C drug with potential adverse effects on a developing fetus.
A topical composition comprising Rapamycin, Monolaurin, and Monomyristin, administered once daily at specific rates, to treat vascular skin abnormalities while maintaining bloodstream concentrations below undesirable levels.
Effectively treats vascular skin abnormalities without Rapamycin accumulation in the bloodstream, reducing side effects and ensuring safety for pregnant women.
Abstract
Description
/ 16 RAPAMYCIN TREATMENT METHOD AND COMPOSITION TECHNICAL FIELD
[001] This invention relates to a Rapamycin composition for administration to humans and to a method of producing or using it. BACKGROUND
[002] Rapamycin was isolated in or around 1972 from samples of Streptomyces hygroscopicus. The compound was initially developed as an antifungal agent and its production is described in US Patent No. 3929992 by Ayerst McKenna & Harrison. Rapamycin has the following structural formula:
[003] One problem with Rapamycin is that it often needs to be used for an extended period and, over time, it can accumulate in the bloodstream at undesirable levels, leading to adverse side effects such as stomatitis, pneumonitis, hyperlipidemia, anemia, thrombocytopenia, renal toxicity, joint pain, and edema. Additionally, Rapamycin is a Category C drug classified by the U.S. FDA, for which animal studies have demonstrated an adverse effect on a developing fetus, which is potentially a problem for pregnant women with undesirable amounts of Rapamycin in their system. OBJECTIVE OF THE INVENTION
[004] It is an object of a preferred embodiment of the invention. Petition 870250103355, dated 12 / 11 / 2025, page 8 / 49 / 16 to solve at least part of the above problem. Although this applies to the preferred embodiment, it should be understood that the objective of the invention itself is not so limited and is simply to provide the public with a useful choice. Therefore, any objects, advantages or benefits of any preferred embodiment should not be inferred as limitations on any claims expressed more broadly. DEFINITIONS
[005] The term “comprising” or its derivatives, for example “comprises”, when used in this document in relation to a combination of features or steps, should not be interpreted as excluding the possibility of there being additional features or steps that have not been mentioned. Therefore, the term is inclusive, not exclusive. SUMMARY OF THE INVENTION First Aspect - Treatment Method
[006] According to a first aspect, the invention is a method of treating a vascular abnormality of the skin of a human individual, comprising administering topically to the abnormality a composition comprising: a) Rapamycin; b) Monolaurin and Monomyristin as carriers; and c) water; once a day at a rate of: d) 4 -8 mg of Rapamycin / cm2; and / or e) 1-6 mg of Rapamycin. Second Aspect - Use in Manufacturing
[007] According to a first aspect, invention is the use of a) Rapamycin; b) Monolaurin and Monomyristin as carriers; and c) water; Petition 870250103355, dated 12 / 11 / 2025, p. 9 / 49 / 16 concerning the manufacture of a composition for the treatment of a vascular skin abnormality in a human individual by topically administering the composition to the abnormality once daily at a rate of: d) 4 -8 mg of Rapamycin / cm2; and / or e) 1-6 mg of Rapamycin. Third Aspect - Composition for Treatment
[008] According to a third aspect, the invention is a composition comprising a) Rapamycin; b) Monolaurin and Monomyristin as carriers; and c) water; For the treatment of a vascular skin abnormality in a human individual, administering the composition topically to the abnormality once daily at a rate of: d) 4 -8 mg of Rapamycin / cm2; and / or e) 1-6 mg of Rapamycin. Fourth Aspect - Additional Treatment Method
[009] According to a fourth aspect, the invention is a method of treating a vascular abnormality in the skin of a human individual, comprising applying topically to the abnormality, once a day, for at least 1, 2, 3, 4, 5 or 6 months, a composition comprising: a) Rapamycin as the active ingredient; b) vehicle comprising Monolaurin and Monomyristin, and c) water as solvent;
[0010] such that at the conclusion of at least 1, 2, 3, 4, 5 or 6 months, the concentration of Rapamycin in the individual's bloodstream, if any, does not exceed 1, 2, 3, 4 or 5 ng / mL (and preferably does not exceed 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9 mg / mL at the conclusion of one or more of the months). For the avoidance of doubt, any of the ng / mL values here Petition 870250103355, dated 12 / 11 / 2025, p. 10 / 49 / 16 mentioned may be applied for any period of time mentioned herein. Optional Features
[0011] The following optional features apply to all first, second, third and fourth aspects of the invention, in each case individually or in any combination with one or more of the following features or sets of features, except where they are mutually exclusive. Administration Fee
[0012] The compound is administered or is for administration, once a day at a rate of: a) 5-7 mg of Rapamycin / cm2; or b) 2-5 mg of Rapamycin.
[0013] The compound is administered or is for administration, once a day at a rate of: c) around 6 mg of Rapamycin / cm2; or d) 3-4 mg of Rapamycin.
[0014] The composition is administered for at least 1, 2, 3, 4, 5 or 6 months.
[0015] The composition is administered or is for administration, such that at the end of at least 1, 2, 3, 4, 5 or 6 months the concentration of Rapamycin in the individual's bloodstream, if any, does not exceed 1, 2, 3, 4 or 5 ng / mL.
[0016] The composition is administered or is for administration, such that at the end of at least 1, 2, 3, 4, 5 or 6 months the concentration of Rapamycin in the individual's bloodstream, if any, does not exceed 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9 ng / mL. Quantities of Components
[0017] The composition comprises 0.5 - 5% by weight of Rapamycin. Petition 870250103355, dated 12 / 11 / 2025, page 11 / 49 / 16
[0018] The composition comprises 0.5 - 1% by weight of Rapamycin.
[0019] The composition comprises approximately 0.5% of Rapamycin.
[0020] The composition comprises approximately 1% of Rapamycin. Conditions Treated
[0021] The vascular abnormality comprises angiofibroma.
[0022] The vascular abnormality comprises facial angiofibroma.
[0023] Vascular abnormality comprises a cutaneous vascular lesion.
[0024] The vascular abnormality includes port-wine stain type lesions.
[0025] Port-wine stain lesions are treated after laser treatment. Additional Features
[0026] The composition comprises Monolaurin in approximately - 28% by weight or approximately 5% - 10% by weight or approximately 7% by weight.
[0027] The composition comprises Monomyristin at approximately 7%-28% by weight or approximately 15%-25% by weight or approximately 21% by weight.
[0028] The composition comprises: a) 5% - 9% by weight of Monolaurin + 19% - 23% by weight of Monomyristin; or b) 12% - 16% by weight of Monolaurin + 12% - 16% by weight of Monomyristin.
[0029] The composition comprises: a) approximately 7% by weight of Monolaurin + approximately 21% by weight of Monomyristin; or Petition 870250103355, dated 12 / 11 / 2025, page 12 / 49 / 16 b) approximately 14% by weight of Monolaurin + approximately 14% by weight of Monomyristin. Water Retention Agent
[0030] The composition comprises a water-retaining agent.
[0031] The water-retaining agent comprises polyoxyethylene stearate. Softening Agent
[0032] The composition includes a softening agent.
[0033] The softening agent comprises one or more of the following: propylene glycol, petrolatum, lanolin, mineral oil, glycerin, lecithin, and sorbitol. Buffer Agent
[0034] The composition comprises a buffering agent.
[0035] The buffering agent comprises one or more of the following: anhydrous citric acid, sodium bicarbonate, and triethanolamine. Kidnapping Agent
[0036] The composition includes a kidnapping agent.
[0037] The sequestering agent comprises one or more of the following: disodium edetate, citric acid, and tetrasodium EDTA. pH Adjusting Agent
[0038] The composition includes hydroxide for pH adjustment. Preservative Agent
[0039] The composition includes a preservative.
[0040] The preservative agent comprises one or more of the following: potassium sorbate, diazolidinyl urea, phenoxyethanol, and sodium hydroxymethylglycinate. Water
[0041] The composition comprises 58% - 72% water by weight. Other Characteristics
[0042] The composition comprises: a) 0.5 - 5% by weight of Rapamycin; Petition 870250103355, dated 12 / 11 / 2025, page 13 / 49 / 16 b) vehicle comprising: • 7-28% by weight of Monolaurin; and • 7-28% by weight of Monomyristin; and c) water as solvent.
[0043] The composition comprises 0.5 - 5% by weight of Rapamycin, 5% - 9% by weight of Monolaurin and 19% - 23% by weight of Monomyristin.
[0044] The composition comprises 0.5 - 5% by weight of Rapamycin, 7% by weight of Monolaurin and 21% by weight of Monomyristin.
[0045] The composition comprises 0.5% or 1% by weight of Rapamycin, 7% by weight of Monolaurin and 21% by weight of Monomyristin.
[0046] The composition comprises 0.5 - 5% by weight of Rapamycin, 12% - 16% by weight of Monolaurin and 12% - 16% by weight of Monomyristin.
[0047] The composition comprises 0.5 - 5% by weight of Rapamycin, 14% by weight of Monolaurin and 14% by weight of Monomyristin.
[0048] The composition comprises 0.5% or 1% by weight of Rapamycin, 14% by weight of Monolaurin and 14% by weight of Monomyristin.
[0049] The composition comprises 0.5 - 5% by weight of Rapamycin, 17.5% (±2%) by weight of Monolaurin and 10.5% (±2%) by weight of Monomyristin.
[0050] The composition comprises 0.5 - 5% by weight of Rapamycin, 17.5% by weight of Monolaurin and 10.5% by weight of Monomyristin.
[0051] The composition comprises 0.5% or 1% by weight of Rapamycin, 17.5% by weight of Monolaurin and 10.5% by weight of Monomyristin.
[0052] The composition comprises 0.5% or 1% by weight of Rapamycin, 21% by weight of Monolaurin and 7% by weight of Monomyristin.
[0053] Monolaurin is glyceryl monolaurate and Monomyristin is glyceryl monomyristate.
[0054] The composition comprises: Petition 870250103355, dated 12 / 11 / 2025, p. 14 / 49 / 16 a) 0.5 - 5% by weight of Rapamycin; b) vehicle comprising: • 10-18% by weight of Monolaurin; and • 10-18% by weight of Monomyristin; and c) water as a solvent. All Declarations
[0055] The composition components listed for any of the aspects or options above may be ±5% or ±10% of the observed values. For example, 0.5% Rapamycin, ±5% of that value, or 1% Rapamycin, ±5% of that value. IMAGES
[0056] Some preferred embodiments of the invention are illustrated by the following images, of which: Figure 1 shows the results obtained from the particle size analysis of a composition with 1% Rapamycin for topical application; Figure 2 shows images of Rapamycin particles in the same composition at 1%; and Figure 3 provides "before and after" images of the skin of a person whose angiofibromas were treated according to an embodiment of the invention. DETAILED DESCRIPTION Example Formulations 1 and 2
[0057] Two preferred embodiments of the invention, namely, the Formulation 1 and Formulation 2 are for the topical treatment of vascular skin abnormalities. Without limiting the scope of the invention, these conditions may include human angiofibromas, for example, facial angiofibromas or cutaneous vascular lesions. The formulations can also be used for the treatment of port-wine stain-type lesions, for example, after Petition 870250103355, dated 12 / 11 / 2025, page 15 / 49 / 16 laser treatment to limit the possible regrowth of the spot. They are composed substantially as shown in Table 1 below: Table 1 Component Function Quantity (% by weight) Formulation 1 Formulation 2 Rapamycin Active ingredient 0.50 1.00 Monolaurin (Glyceryl monolaurate) Vehicle 7.00 7.00 Monomyristin (Glyceryl monomyristate) Vehicle 21.00 21.00 Polyoxyethylene stearate (100) Water retaining agent 1.00 1.00 Propylene glycol Softening agent 2.00 2.00 Anhydrous citric acid Buffer agent 0.90 0.90 Disodium edetate Sequestrant agent 0.05 0.05 Sodium hydroxide pellets pH adjusting agent 0.18 0.18 Potassium sorbate Preservative agent 0.20 0.20 Purified water Solvent agent 67.17 66.67
[0058] The compositions according to the invention, including the Formulations 1 and 2 can be produced according to the following method. Production of an aqueous phase pre-blend
[0059] An aqueous phase pre-blend is prepared as follows: • Rapamycin and propylene glycol are combined and mixed in a vortex; • Water is added with continuous vortex mixing; • The mixture is then heated to 70 °C (± 5 °C); • Citric acid, disodium EDTA, and potassium sorbate are added and mixed in a vortex until dissolved; • the temper of the mixture is then adjusted to 50; and • polyoxyethylene stearate (100) is added. Production of an oil-phase pre-blend
[0060] An oil-phase pre-blend is prepared as follows: Petition 870250103355, dated 12 / 11 / 2025, page 16 / 49 / 16 • Glyceryl monolaurate and glyceryl monomyristate are combined with slow-speed vortex mixing and heating at 70 °C (± 5 °C). final blend
[0061] The aqueous and oil phase pre-blends, both at 70 °C (± 5 °C), are combined and thoroughly mixed until homogeneous. The mixture is then slowly cooled at a rate of 1 °C per minute and vortexed until a smooth, white, iridescent cream is formed. Once the cream has cooled to no more than 32 °C, it is packaged in 30 mL aluminum tubes with polypropylene screw caps. Example Formulations 3 and 4
[0062] Formulations 3 and 4 were produced for the same purpose and described in the same manner as Formulations 1 and 2. They are listed in Table 2 below: Table 2 Component Function Quantity (% by weight) Formulation 3 Formulation 4 Rapamycin Active ingredient 0.10 5.00 Monolaurin (Glyceryl monolaurate) Vehicle 7.00 7.00 Monomyristin (Glyceryl monomyristate) Vehicle 21.00 21.00 Polyoxyethylene stearate (100) Water retaining agent 1.00 1.00 Propylene glycol Softening agent 2.00 2.00 Anhydrous citric acid Buffering agent 0.90 0.90 Disodium edetate Sequestrant agent 0.05 0.05 Sodium hydroxide pellets pH adjusting agent 0.18 0.18 Potassium sorbate Preservative agent 0.20 0.20 Purified water Solvent agent 72 66.1 Particle Size Characteristics
[0063] Figures 1 and 2 illustrate properties of the active ingredient. Rapamycin for the 1% cream identified above as Formulation 2. Petition 870250103355, dated 12 / 11 / 2025, page 17 / 49 / 16 information was obtained by analyzing the Formulation using a Malvern Morphologi GS3 image analyzer. This is effectively an automated microscope that scanned the Formulation to detect three-dimensional features of the Rapamycin particles.
[0064] With reference to Figure 1, the EC Diameter ('circular equivalent diameter') values represent particle size on a number-weighted basis. In other words, they represent the particles as two-dimensional shapes converted to the nearest applicable circle, for which the diameter is then calculated. Referring to the particular notation shown, D[n,0.10](gm): 3.17 means that 10% of the particles are 3.17 pm or smaller based on the number of particles; D[n,0.16] (pm): means that 16% are smaller than 3.83 μm; and D[n,0.50] (pm): means that 50% are smaller than 8.33 pm based on the number of particles, etc.
[0065] With reference to Figure 2, the images are representative of the shape and relative size of Rapamycin particles in Formulation 2.
[0066] Figures 1 and 2 illustrate that Rapamycin is not dissolved in the rest of the composition, but rather remains suspended in the carrier component or vehicle. Tests - Blood Concentration of Rapamycin Method
[0067] A multicenter, double-blind, randomized, placebo-controlled, dose-response, parallel-test was conducted in accordance with the Declaration of Helsinki and the International Council for Harmonization Guidelines for Good Clinical Practice. Its objective was to evaluate the efficacy in the topical treatment of vascular skin abnormalities, including whether, and if so, to what extent, Rapamycin transfers into the bloodstream when applied topically via Formulation 1 or Formulation 2. Petition 870250103355, dated 12 / 11 / 2025, page 18 / 49 / 16
[0068] The study comprised 107 human participants aged between 6 and 65 years diagnosed with facial angiofibromas associated with tuberous sclerosis complex. The facial angiofibromas were of mild or moderate severity. In other words, each individual had a score of 2 or 3 on an Investigator Global Assessment (IGA) scale.
[0069] Participants were randomized into one of three treatment groups: 0.5% Rapamycin cream (Formulation 1; n = 36), 1% Rapamycin cream (Formulation 2; n = 33), or placebo cream (i.e., the same excipients but without the active ingredient; n = 38).
[0070] The formulations and placebo were applied to the angiofibromas topically, once daily, for 26 weeks at a rate of Rapamycin of 6 mg / cm2 of skin. Given that different participants had different sized areas of angiofibromas, not all received the same amount of formulation. However, the average amount of Rapamycin administered per day across the group was as shown in Table 3 below: Table 3 Formulations 1 and 2 Age Formulation Average amount of cream per person (mg / day) Average amount of Rapamycin per person (mg / day) <12 1 (0.5%) 379 1.895 <12 2 (1%) 277 2.77 >12 1 (0.5%) 460 2.3 >12 2 (1%) 567 5.67
[0071] The safety and effectiveness measures were evaluated on the 14th, 56, 98, 140 and 182 (Visits 1-5, respectively). The primary outcome was based on IGA scores after 26 weeks of treatment.
[0072] The secondary evaluation criteria included Index of Severity of Facial Angiofibromas (FASI) and improvement based on percentage reported by the individual and the physician. Petition 870250103355, dated 12 / 11 / 2025, page 19 / 49 / 16
[0073] All treated participants were included in the final analysis. Results
[0074] The degree of improvement at the end of the treatment period is indicated in Table 4 as follows: Table 4 Number of participants Formulation 1 (0.5% Rapamycin) n=36 Formulation 2 (1% Rapamycin) n=33 Placebo n=38 Total N = 107 Two-grade reduction in IGA score 4 (11.1%) 3 (9.1%) 2 (5.3%) 9 (8.4%) One-grade reduction in IGA score 20 (55.6%) 20 (60.6%) 9 (23.7%) 49 (45.8%)
[0075] Participants who did not have an improved IGA score of at least 1 are not included in the results above.
[0076] An example of the reduction in facial angiofibromas achieved for a person in the trial who was treated as above with Formulation 2 is illustrated in Figure 3. This individual had an IGA Score of 3 at baseline and an IGA Score of 2 at Visit 5.
[0077] Table 5 below reports the amount of Rapamycin found in the blood of various participants. The value of 'N' for the number of participants tested for each Visit is less than the number enrolled in each group because some did not provide a test sample. In some cases, this was due to the reluctance of pediatric (child) participants to donate blood at some testing points. For example, for 1% Rapamycin at Visit 1, the number of individuals tested was N=26 compared to N=33 for the total number enrolled in the Trial for that group. However, no Rapamycin was detected for any participants who returned test samples at any testing stage, except that in Test 1 (14 days) one participant in the 0.5% formulation group had 1.1 ng / ml of Rapamycin in their blood. Petition 870250103355, dated 12 / 11 / 2025, page 20 / 49 / 16 Table 5. Rapamycin blood concentration changes from baseline over time. Formulation 1: 0.5% Rapamycin; Formulation 2: 1% Rapamycin; Placebo; Total. Baseline Value (N): 36, 33, 38, 107. Visit 1: 1.1 ng / mL; Zero; Change from baseline: Zero to 1.1; Zero to zero; 1; 29; 1 (2.8%); 29 (80.6%); 0; 26; 0 (0%); 26 (78.8%); 27; 0 (0%); 27 (71.1%); 82; 0.9 (0%); 82 (76.6%). Visit 2: Zero; Change from baseline: Zero to zero; 27; 27 (75.0%); 26; 26 (78.8%); 28; 28 (73.7%); 81; 81 (75.7%). Visit 3: Zero; Change from baseline: Zero. Visit 4: Zero Change from baseline Zero to zero 29 29 (80.6%) 27 27 (78.8%) 23 23 (60.5%) 69 69 (64.5%) Visit 5: Zero Change from baseline Zero to zero 24 24 (66.7%) 20 20 (60.6%) 21 21 (55.3%) 65 65 (60.7%) Visit 6: Zero Change from baseline Zero to zero 30 30 (83.3%) 27 27 (81.8%) 34 34 (89.5%) 91 91 (85.0%) Follow-up Visit: Zero Change from baseline Zero to zero 23 23 (63.9%) 20 20 (60.6%) 20 20 (52.8%) 63 63 (58.9%)
[0078] In the study, both Formulations 1 and 2 were well tolerated and were effective in reducing facial angiofibromas in most participants. Notably, this was achieved without Rapamycin reaching the bloodstream, with the sole exception indicated above for the 14-day test, but this did not occur again in any subsequent test stages / visits. At 6 months, none of the participants who were tested had any Rapamycin in their blood. These results are remarkable, given that the transfer of Rapamycin to the blood was expected, especially given the duration of the period during which the drug was being taken and the amount administered. Petition 870250103355, dated 12 / 11 / 2025, page 21 / 49 / 16
[0079] For comparison, the commercial product HYFTOR™ Gel1 was tested. This is a topical gel containing 0.2% by weight of Rapamycin for the treatment of tuberous sclerosis and similar diseases. The product was applied topically twice daily to 30 human participants at angiofibroma sites. The average total amount dosed per participant per day is shown in Table 6 below: Table 6 HYFTOR™ Gel Dosage Rate Age Average amount of HYFTOR™ Gel per person (mg / day) Average amount of Rapamycin per person (mg / day) <12 600 1.2 >12 800 1.6
[0080] Tests were carried out to determine the amount of Rapamycin in the bloodstream during the period in which HYFTOR™ Gel was administered, with the results observed in Table 7 as follows: Table 7 HYFTOR™ Gel Blood Results N Number of patients with Rapamycin in blood Average amount of Rapamycin (ng / ml) Maximum amount of Rapamycin (ng / ml) Tested over 4 weeks All patients 30 27 (90%) 0.22 0.39 Pediatric patients 13 12 (92%) 0.19 0.29 Adults 17 15 (88%) 0.24 0.39 Tested over 12 weeks All patients 30 21 (70%) 0.24 0.50 Pediatric patients 13 10 (77%) 0.21 0.41 Adults 17 11 (65%) 0.27 0.50 Comparison Formulations 1 and 2, versus HYFTOR™ Gel
[0081] As can be seen in Tables 3 and 6, with Formulations 1 and 2, a larger amount of Rapamycin was administered to the trial participants compared to HYFTOR™ Gel. In the case of Formulation 2,1https: / / www.hyftor.com. Petition 870250103355, dated 12 / 11 / 2025, page 22 / 49 / 16 in particular, individuals aged > 12 years received, on average, 5.67 mg / day of Rapamycin, compared to 1.6 mg / day for individuals in the same age range who used HYFTOR™ Gel.
[0082] Notwithstanding the greater quantity of Rapamycin for the Formulation 2: Rapamycin did not accumulate in the body / bloodstream, whereas HYFTOR™ Gel did. This suggests that formulations based on Monolaurin and Monomyristin vehicles can be used more safely to dispense larger amounts of Rapamycin to patients who require higher doses.
[0083] Furthermore, the results indicate that, even for people who only need lower amounts of Rapamycin, formulations based on Monolaurin and Monomyristin reduce the likelihood of Rapamycin accumulating in the body / bloodstream. Description
[0084] In terms of description, this document describes each item, feature or step mentioned herein in combination with any one or more of the other items, features or steps described herein, in each case regardless of whether such combination is claimed or not. Variations
[0085] Although some preferred embodiments of the invention have been described by way of example, it should be understood that modifications and improvements may occur without departing from the scope of the following claims. Petition 870250103355, dated 12 / 11 / 2025, p. 23 / 49
Claims
1 / 4 CLAIMS 1. Use of ingredients comprising: a) Rapamycin; b) Monolaurin and Monomyristin as vehicle; and c) water; characterized in that it is for the preparation of a medicament in the form of a composition for treating a vascular abnormality of the skin of a human individual by topical administration of the composition onto the abnormality once daily at a rate of: d) 4-8 mg of Rapamycin / cm2; and / or e) 1-6 mg of Rapamycin; wherein the vascular abnormality comprises: f) angiofibroma; g) cutaneous vascular lesion; or h) port-wine stain type lesion.
2. Use according to claim 1, characterized in that the composition is for once-daily administration at a rate of: a) 5-7 mg of Rapamycin / cm2; and / or b) 2-5 mg of Rapamycin.
3. Use according to claim 1, characterized in that the composition is for once-daily administration at a rate of: a) approximately 6 mg of Rapamycin / cm2; and / or b) 3-4 mg of Rapamycin.
4. Use according to claim 1, 2 or 3, characterized in that the composition is for administration for at least 1, 2, 3, 4, 5 or 6 months.
5. Use, according to any of claims 1 to 4, characterized in that the composition is for administration for at least 1, 2, 3, 4, 5 or 6 months, such that, at the conclusion of 1, 2, 3, 4, 5 or 6 Petition 870250113979, dated 11 / 12 / 2025, page 7 / 17 2 / 4 months, the concentration of Rapamycin in the individual's bloodstream, if any, does not exceed 1, 2, 3, 4 or 5 ng / mL.
6. Use, according to any one of claims 1 to 4, characterized in that the composition is for administration in such a way that at the conclusion of at least 1, 2, 3, 4, 5 or 6 months of administration, the concentration of Rapamycin in the individual's bloodstream, if any, does not exceed 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9 ng / mL.
7. Use, according to any of the preceding claims, characterized in that the composition comprises 0.5 - 5% by weight of Rapamycin.
8. Use according to claim 7, characterized in that the composition comprises 0.5 - 1% by weight of Rapamycin.
9. Use according to claim 7, characterized in that the composition comprises approximately 0.5% of Rapamycin.
10. Use according to claim 7, characterized in that the composition comprises approximately 1% of Rapamycin.
11. Use, according to any of the preceding claims, characterized in that the composition comprises Monolaurin in approximately 7-28% by weight or approximately 5%-10% by weight or approximately 7% by weight.
12. Use, according to any of the preceding claims, characterized in that the composition comprises Monomyristin in approximately 7%-28% by weight or approximately 15%-25% by weight or approximately 21% by weight.
13. Use, according to any of the preceding claims, characterized in that the composition comprises: a) 5% - 9% by weight of Monolaurin + 19% - 23% by weight of Monomyristin; or b) 12% - 16% by weight of Monolaurin + 12% - 16% by weight of Monomyristin.
14. Use, according to any of the preceding claims, characterized in that the composition comprises: a) about 7% by weight of Monolaurin + about 21% by weight of Monomyristin; or b) about 14% by weight of Monolaurin + about 14% by weight of Monomyristin.
15. Use, according to any of the preceding claims, characterized in that the composition comprises one or more of a water-retaining agent, a softening agent, a buffering agent, a sequestering agent, a pH-adjusting hydroxide, and a preservative.
16. Use, according to any one of claims 1 to 7, characterized in that the composition comprises 0.5 - 5% by weight of Rapamycin, 17.5% (±2%) by weight of Monolaurin and 10.5% (±2%) by weight of Monomyristin.
17. Use, according to any one of claims 1 to 7, characterized in that the composition comprises 0.5% or 1% by weight of Rapamycin, 21% by weight of Monolaurin and 7% by weight of Monomyristin.
18. Use, according to any of the preceding claims, characterized in that Monolaurin is glyceryl monolaurate and Monomyristin is glyceryl monomyristate.
19. Use, according to any one of claims 1 to 7, characterized in that the composition comprises: a) 0.5 - 5% by weight of Rapamycin; b) vehicle comprising: • 10-18% by weight of Monolaurin; and • 10-18% by weight of Monomyristin; and c) water as solvent.
20. Composition, comprising: Petition 870250113979, dated 11 / 12 / 2025, page 9 / 17 4 / 4 a) Rapamycin; b) Monolaurin and Monomyristin as vehicle; and c) water; characterized in that it is for use in the treatment of a vascular skin abnormality in a human individual by administering the composition topically to the abnormality once daily at a rate of: d) 4-8 mg of Rapamycin / cm2; and / or e) 1-6 mg of Rapamycin; wherein the vascular abnormality comprises: f) angiofibroma; g) cutaneous vascular lesion; h) port-wine stain type lesion. Petition 870250113979, dated 11 / 12 / 2025, page 10 / 17
